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The protein encoded by the CHEK2 gene is involved in cellular repair of DNA damage. The truncating mutation, CHEK2*1100delC,
seems to increase the risk for breast cancer. We investigated whether the CHEK2*1100delC mutation carrier status increases the risk
for asynchronous contralateral breast cancer (CBC) and whether it interacts with radiation therapy (RT) or chemotherapy in regard
to CBC risk. The germline mutation frequency was assessed in 708 women with CBC and 1395 women with unilateral breast cancer
(UBC) in the Women’s Environment, Cancer and Radiation Epidemiology (WECARE) Study whose first primary breast cancer was
diagnosed before age 55 years and during 1985–1999. Seven women with CBC (1.0%) and 10 women with UBC (0.7%) were
CHEK2*1100delC variant carriers (rate ratio (RR)¼1.8, 95% confidence interval (CI)¼0.6–5.4 for CBC vs UBC). Carriers who
received RT for their first breast cancer, compared with non-carriers not treated with RT, had an RR of developing CBC of 2.6 (95%
CI¼0.8–8.7). We found no significant associations between the CHEK2*1100delC mutation and CBC overall or among those
treated with RT. However, the sampling variability was such that modest increases in risk could not be excluded. Nonetheless,
because this is a rare mutation, it is unlikely to explain a major fraction of CBC in the population.
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The CHEK2 gene codes for a protein that is involved in cell-cycle
control and DNA repair. A protein-truncating mutation in the
gene, 1100delC, was associated with a two-fold increase in breast
cancer risk in the CHEK2 Breast Cancer Case–Control Consortium
pooling project, which comprised 10860 breast cancer cases and
9065 controls from 10 studies in five countries (The CHEK2 Breast
Cancer Case–Control Consortium, 2004). The prevalence of the
CHEK2*1100delC variant among women with and without breast
cancer varies among countries (Meijers-Heijboer et al, 2002;
Vahteristo et al, 2002; Osorio et al, 2004; Huzarski et al, 2005;
Kilpivaara et al, 2005; Bernstein et al, 2006; Weischer et al, 2007).
A higher prevalence of the mutation has been found among
patients with bilateral breast cancer (Broeks et al, 2004; Kilpivaara
et al, 2005) and among patients with a family history of breast
cancer (Meijers-Heijboer et al, 2002; Vahteristo et al, 2002;
Friedrichsen et al, 2004). Carriers of the CHEK2*1100delC
mutation are hypothesised to have an increased sensitivity to
exposures such as radiation therapy (RT) and chemotherapy that
cause DNA double-strand breaks, as the CHEK2 regulates cell-
cycle checkpoint response pathways that respond to such damage
(Nevanlinna and Bartek, 2006). We investigated the risk for
contralateral breast cancer (CBC) associated with the
CHEK2*1100delC germline mutation among approximately 2100
women with breast cancer who were cases and controls in the
multicentre Women’s Environment, Cancer and Radiation Epide-
miology (WECARE) Study (Bernstein et al, 2004). In addition, we
explored the joint effect of being a carrier of mutated CHEK2 and
having received RT or chemotherapy for breast cancer.
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sMATERIALS AND METHODS
Study population
Cases in this study were women with asynchronous CBC and
controls were women with unilateral breast cancer (UBC) obtained
from the WECARE Study (Bernstein et al, 2004). The participants
were identified through five population-based cancer registries:
four in the United States (Surveillance Epidemiology and End
Results (SEER) registries in Iowa, Seattle, Los Angeles County and
Orange County/San Diego) and one in Denmark (Danish Breast
Cancer Cooperative Group (DBCG) registry supplemented by data
from the Danish Cancer Registry). Case women were eligible for
the study if they were under age 55 years at diagnosis of their first
invasive breast cancer and were diagnosed with a second primary
breast cancer in the contralateral breast (invasive or in situ) at least
1 year later, while residing in the same reporting area at the time of
diagnosis of both cancers with no history of a prior cancer
diagnosis or an intervening cancer diagnosis between their first
and second primary breast cancers. All first primary breast cancers
were invasive without distant metastases and were diagnosed
between 1 January 1985 and 31 December 1999. The second
primary breast cancer had to have been diagnosed no later than 31
December 2001. All women were alive at the time of contact.
Control women had to fulfil the same eligibility criteria as cases
except that they had no CBC during the interval between the
matched case woman’s first and second breast cancers (‘at-risk’
period) and had no prophylactic mastectomy during the ‘at-risk’
period. The reference date for case women was the date of
diagnosis of their second primary breast cancer, whereas the
corresponding reference date for control women was defined as
their date of diagnosis of primary breast cancer plus the ‘at-risk’
period for their matched case. Two UBC controls were individually
matched to each CBC case on year of birth (5-year strata), year of
diagnosis (4-year strata), registry region and race, and counter-
matched on RT (as designated by the cancer registry), that is, each
triplet comprised two women who had received RT and one
woman who had not. Counter-matching was used to improve the
statistical efficiency of the study design (Bernstein et al, 2004).
Characteristics of the first and second breast cancers were
abstracted from medical records and cancer registry files. Medical
records were retrieved to obtain detailed information on the
treatment of the first breast cancer (RT, chemotherapy and
hormonal therapy). By the use of methods previously described
(Bernstein et al, 2004), the mean individual radiation dose to the
contralateral breast was estimated as 1.29Gy (range: 0.03–4.68Gy)
(estimation carried out for 85% of those who received RT). Among
women treated with chemotherapy, 54% had received CMF, CF or
CM (C, cyclophosphamide; M methotrexate; F, fluorouracil), 23%
had received CAF, CEF, CMAF, CAM, CMEF or AC (A, adriamycin;
E, epirubicine) and 23% had received other or unknown regimens.
All the women were interviewed by telephone using a structured
questionnaire to obtain information on known breast cancer risk
factors. In addition, for the small subset of women for whom
medical records did not give information on chemotherapy (7%)
and/or hormonal therapy (10%), treatment information was
obtained at the interview. Blood samples were drawn by study
phlebotomists. Study participants were genotyped for mutations in
BRCA1 and BRCA2 genes as previously described (Begg et al,
2008). All participants provided written informed consent before
enrolment into the WECARE Study, and the research protocol was
approved by the respective Institutional Review Boards and the
ethical committee system in Denmark.
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Figure 1 Detection of CHEK2*1100delC by oligonucleotide ligation. (A) Schematic of the method. Total genomic DNA is incubated with three
oligonucleotides. On the CHEK2*1100delC sequence, the oligonucleotides hybridise in juxtaposition on the target sequence and can be joined by ligation
and subsequently amplified by PCR. On the wild-type CHEK2 sequence, two of the oligonucleotides are separated by one base (C) and cannot be ligated
into an amplifiable probe. (B) Analysis of WECARE samples. The controls include DNA samples with (lane 10) and without (lane 11) CHEK2*1100delC,a
ligation control without DNA (lane 12), and a negative PCR control (lane 13). Lane 14, 100bp ladder.
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were eligible and approached to participate in the study, 708 (71%)
cases and 1399 (66%) controls were enrolled. Matching was
successfully carried out for 694 triplets (matching criteria were
relaxed on region or race/ethnicity for 17 triplets) and 11 case–
control pairs, whereas three cases had no matched controls. All 708
cases and 1395 of the controls (99.7%) were genotyped for
CHEK2*1100delC (four controls excluded).
Genotyping of CHEK2*1100delC
For detection of CHEK2*1100delC, we developed an assay based on
ligation-dependent amplification (Figure 1). The sequences of the
oligonucleotides were 50-[TATGTAAAACGACGGCCAGT]-TGGCA
AGTTCAACATTATTCCCTTTTGTACTGAATTTTAGATTA-30,5 0-
TGATTTTGGGCACTCCAAGATTTTGGG-30 and 50-AGAGACCTC
TCTCATGAGAACCTTATGTGGAACC-[ACCCAATTCGCCCTATAA
TA]-30; the latter two oligonucleotides were 50-phosphorylated.
Approximately 50ng of genomic DNA in 5ml TE buffer was
incubated at 981C for 10min and then cooled at 251C. MLPA buffer
(1.5ml; MRC-Holland, Amsterdam, the Netherlands) and 2fmol of
each oligonucleotide were added, and the samples were then
heated at 951C for 1min and incubated at 371C for 16h in a total
volume of 8ml. Ligation of the hybridised oligonucleotides was
achieved by the addition of 32ml of a ligase mix containing 3ml
ligase buffer A (MRC-Holland), 3ml ligase buffer B (MRC-
Holland), 1U Taq DNA ligase (New England Biolabs, Beverly,
MA, USA) and incubation at 541C for 15min. Ligation products
were amplified with primers 50-TATGTAAAACGACGGCCAGT-30
and 50-TATTATAGGGCGAATTGGGT-30. Hybridisation, ligation
and PCR were performed in 96-well plates, which contained two
positive controls (DNA with CHEK2*1100delC), two negative
controls (DNA without CHEK2*1100delC) and two ligation
controls (without DNA). The PCR products were resolved by
agarose gel electrophoresis.
The reliability of the ligation assay was confirmed by re-analysis
of 248 DNA samples from WECARE Study participants using
denaturing gradient gel electrophoresis (DGGE), as described
previously (Bartkova et al, 2004). We found complete concordance
between the results obtained with these two methods (3 out of 248
samples screened were positive for mutations). The remaining
1855 samples were then analysed with the ligation assay. All
positive results were reconfirmed by DGGE analysis or with the
ligation assay for samples where long-range amplification was
unsuccessful.
Statistical methods
Rate ratios (RRs) and corresponding 95% confidence intervals
(CIs) were estimated by univariate conditional logistic regression
models accounting for the counter-matched design (details
described previously; Bernstein et al, 2004). Multivariable models
were adjusted for exact age at diagnosis of the first primary breast
cancer, age at menarche (o13/X13 years), menopausal status at
reference date (premenopausal/age at menopause o45 years/age at
menopause X45 years), number of full-term pregnancies (0, 1, 2,
3, X4), family history of breast cancer among first-degree relatives
(yes/no), lobular histology of the first primary (yes/no), stage of
Table 1 Frequency of CHEK2*1100delC carrier status among women with asynchronous CBC and UBC in the WECARE Study according to age at first
breast cancer, race, study centre, family history of breast cancer and estrogen receptor status of first breast cancer
Asynchronous CBC (n¼708) UBC (n¼1395)
Carrier Non-carrier Carrier Non-carrier
All (n and %) 7 (1.0) 701 (99.0) 10 (0.7) 1385 (99.3)
Age at first breast cancer (n and %)
o45 years 2 (0.7) 289 (99.3) 6 (1.1) 562 (98.9)
X45 years 5 (1.2) 412 (98.8) 4 (0.5) 823 (99.5)
Race (n and %)
Non-Hispanic white 7 (1.1) 642 (98.9) 10 (0.8) 1276 (99.2)
Hispanic white 0 (—) 24 (100.0) 0 (—) 46 (100.0)
Black 0 (—) 21 (100.0) 0 (—) 39 (100.0)
Asian 0 (—) 13 (100.0) 0 (—) 22 (100.0)
Other 0 (—) 1 (100.0) 0 (—) 2 (100.0)
Study centre (n and %)
Los Angeles County, CA 1 (0.5) 198 (99.5) 1 (0.3) 390 (99.7)
Seattle 1 (1.0) 98 (99.0) 0 (—) 193 (100.0)
Iowa 3 (2.7) 110 (97.3) 4 (1.8) 224 (98.2)
Orange County/San Diego, CA 0 (—) 118 (100.0) 2 (0.9) 227 (99.1)
Denmark 2 (1.1) 177 (98.9) 3 (0.8) 351 (99.2)
Family history of breast cancer (n and %)
At least one first-degree relative with breast cancer
a 3 (1.3) 223 (98.7) 5 (1.7) 284 (98.3)
At least one second-degree relative with breast cancer
a 3 (1.1) 274 (98.9) 2 (0.5) 409 (99.5)
At least one relative with bilateral breast cancer
a 1 (6.7) 14 (93.3) 0 (—) 18 (100.0)
Unknown family history, adopted 0 (—) 11 (100.0) 0 (—) 26 (100.0)
Estrogen receptor status, first breast cancer (n and %)
Positive 4 (1.2) 334 (98.8) 4 (0.5) 739 (99.5)
Negative 3 (1.6) 190 (98.4) 3 (0.9) 335 (99.1)
Other or unknown 0 (—) 177 (100.0) 3 (1.0) 311 (99.0)
CBC¼contralateral breast cancer; WECARE¼Women’s Environment, Cancer and Radiation Epidemiology; UBC¼unilateral breast cancer.
aWomen may be in more than one
of these categories.
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(yes/no) and hormonal therapy (yes/no). As results of the
univariate and multivariable models were quite similar, we present
RRs from the univariate models. In addition, we present RRs from
models adjusted for BRCA1/2 carrier status (deleterious BRCA1/2
mutations yes/no/unknown). The TPHREG procedure in SAS
release 9.1 (SAS Institute Inc., Cary, NC, USA) was used for the
statistical analyses. Further information about the SAS program-
ming used for counter-matched WECARE data is provided in the
appendix of Bernstein et al (2004).
RESULTS
The mean length of time since first breast cancer diagnosis was 5.0
years (range: 1–15.6 years) for the total study population. Seven
(1.0%) carriers of the CHEK2*1100delC germline mutation were
found among the 708 women with CBC, whereas 10 (0.7%) carriers
were found among the 1395 women with UBC. Characteristics of
carriers and non-carriers among cases and controls are shown in
Table 1.
The association between being carrier of the CHEK2*1100delC
mutation and risk of developing CBC was not statistically
significant (RR¼1.7; 95% CI¼0.6–5.1) (Table 2). Compared to
women who did not carry the mutation and who did not receive
RT for their first breast cancer, carriers who received RT as
treatment had an RR of CBC of 2.6 (95% CI¼0.8–8.4). The RR of
CBC among mutation carriers treated with chemotherapy was 1.3
(95% CI¼0.3–6.2) compared with non-carriers who did not
receive chemotherapy. We had 90% statistical power at two-sided
Po0.05 to exclude a RR of 6.0 for CBC associated with the
CHEK2*1100delC mutation overall, a RR of 6.9 for the combination
of the mutation and RT and a RR of 13.1 for the combination of the
mutation and chemotherapy. The RR for the CHEK2*1100delC
mutation and CBC overall was largely unchanged after the
adjustment for BRCA1/2 carrier status (RR¼1.8; 95% CI¼0.6–
5.4) as were the RRs for the mutation in combination with RT or
chemotherapy (Table 2).
Results of analyses restricted to non-Hispanic whites (649
women with CBC and 1286 women with UBC) were similar to those
for all study subjects combined.
DISCUSSION
In this population-based multicentre study, we found a low
prevalence of CHEK2*1100delC mutation carriers among 708
women with CBC (1.0%) and 1395 women with UBC (0.7%).
Several studies have shown higher frequencies (ranging from 1.7 to
14.3%) of mutation among women with bilateral breast cancer
(Oldenburg et al, 2003; Broeks et al, 2004; Kilpivaara et al, 2005;
Chekmariova et al, 2006; Kwiatkowska et al, 2006); however, none
of these were population-based. Two of these studies reported that
the frequency of mutation was significantly increased among
women with bilateral breast cancer compared to women with UBC
(Broeks et al, 2004; Kilpivaara et al, 2005). Also, a small but
prospective study reported a significant increase in risk for CBC
among mutation carriers (de Bock et al, 2004). Three previous
studies showing a high carrier prevalence among bilateral breast
cancer cases were from the North European countries, the
Netherlands (Oldenburg et al, 2003; Broeks et al, 2004) and
Finland (Kilpivaara et al, 2005). Although the carrier prevalence
among Danish WECARE Study participants is low relative to these
prior reports, the prevalence among Danish participants with UBC
is similar to that observed in a previous Danish study (Weischer
et al, 2007). Differences in frequencies across studies may also be
due to differences in study selection criteria, for example,
restriction to certain ages at the onset of breast cancer and/or to
subjects with family history defined in various ways. Only one of
the previous studies on bilateral breast cancer was restricted to
non-BRCA1/2 mutation cases (Oldenburg et al, 2003). In contrast
to all the previous studies on bilateral breast cancer, which were
based on cases from cancer hospitals or genetics clinics, our study
is the first that is population-based.
The CHEK2*1100delC allele is hypothesised to interact with
environmental factors to promote breast tumorigenesis. Ionising
radiation is of particular interest because it induces DNA damage,
and the protein of the CHEK2 gene is a kinase that plays a role in
response to such damage by delaying cell-cycle progression to
facilitate DNA repair or even induce cell death (Nevanlinna and
Bartek, 2006). The germline mutation 1100delC truncates the
CHEK2 protein, thereby abolishing the kinase function (Wu et al,
2001). Epidemiological evidence to substantiate increased radio-
sensitivity among carriers is, however, sparse (Bernstein et al,
2006; Broeks et al, 2007). Also, although a study conducted in
Table 2 Risk for asynchronous CBC associated with CHEK2*1100delC mutation carrier status overall and in combination with RT or chemotherapy for
the first breast cancer
Univariate
b Adjusted
c
No. with asynchronous
CBC (n¼705
a) No. with UBC (n¼1395) RR 95% CI RR 95% CI
Mutation
No 698 1385 1.00 — 1.00 —
Yes 7 10 1.7 0.6–5.1 1.8 0.6–5.4
Mutation RT
No no 359 263 1.00 — 1.00 —
No yes 339 1122 1.1 0.9–1.3 1.0 0.9–1.2
Yes no 2 2 0.6 0.1–4.2 0.7 0.1–5.4
Yes yes 5 8 2.6 0.8–8.4 2.6 0.8–8.7
Mutation chemotherapy
No no 381 622 1.00 — 1.00 —
No yes 317 763 0.6 0.5–0.7 0.6 0.5–0.7
Yes no 4 5 1.4 0.3–6.3 1.6 0.4–7.6
Yes yes 3 5 1.3 0.3–6.2 1.2 0.3–5.7
CBC¼contralateral breast cancer; CI¼confidence interval; RR¼rate ratio; RT¼radiation therapy; UBC¼unilateral breast cancer.
aThree cases without matched controls
excluded.
bRRs adjusted for counter-matching sampling.
cRRs adjusted for counter-matching sampling and BRCA1/2 carrier status.
Breast cancer and the CHEK2*1100delC mutation
L Mellemkjær et al
731
British Journal of Cancer (2008) 98(4), 728–733 & 2008 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sBelgium suggested that breast cancer patients with a CHEK2*1100-
delC mutation are, in general, not characterised by a distinct
enhanced chromosomal radiosensitivity, this conclusion was based
on only four breast cancer cases with the mutation who
were compared with healthy controls without the mutation
(Baeyens et al, 2005). Our result, although not statistically
significant, suggests that mutation carriers may have increased
radiosensitivity.
The WECARE Study was designed to investigate interactions
between genes and exposures that cause DNA double-strand
breaks in a study population enriched with hereditary breast
cancer cases, owing to the restriction to early-onset breast cancer,
and a population heavily exposed to ionising radiation and
chemotherapeutic drugs. Detailed information on RT and che-
motherapy was obtained by a thorough review of medical records.
As DNA samples from WECARE Study participants have also been
screened for mutations in BRCA1 and BRCA2 genes, we were able
to adjust the analyses for BRCA carrier status. Patients included in
the study survived varying lengths of time from reference date to
interview; however, cases and controls within each triplet survived
approximately the same length of time. The prevalence of the
mutation may have been affected if carriers of the CHEK2*1100-
delC mutation had a worse survival than non-carriers. Unfortu-
nately, we could not address this question, as we had no
information on carrier status among the non-survivors who were
not included in the study. Previous studies have shown a worse
recurrence-free survival (Schmidt et al, 2007) and distant
metastases-free survival (de Bock et al, 2004) among carriers
compared to non-carriers, but overall survival did not differ by
carrier status (de Bock et al, 2004).
Notably, we found a low carrier frequency for the CHEK2*1100-
delC mutation in this large population-based sample of early-onset
cases of CBC and UBC. The small number of carriers reduced our
ability to study the effects of the mutation on the development of
CBC; and accordingly, we could not exclude the possibility that the
CHEK2*1100delC mutation is associated with modest increases
in risk. In contrast, the rarity of the CHEK2*1100delC mutation
indicates that it plays a rather limited role in the aetiology of CBC
in the population.
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